Alain Rupin

This inventor holds 17 USPTO granted patents, plus 2 CIPO patents and 3 EPO patents. Top assignees: Adir Et Compagnie, Les Laboratoires Servier, Les Laboratories Server. Active years: 1995-2020.

USPTO Granted Patents = 17

% Patents Active = 58.8

CIPO Patents = 2

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 5.7

ph-index = 6

Forward Citations = 131(Granted Patents)

Company Filing History:

Les Laboratoires Servier

patents

2 out of 3

Les Laboratories Server

patents

4. 2 out of 53

Les Laboratories Servier

patents

5. 1 out of 5,383

Centre National De La Recherche Scientifique

patents

6. 1 out of 1

L'institut National Des Sciences Appliquées De Rouen

patent

7. 1 out of 1

L'universite De Rouen

patent

where one patent can have more than one assignee

Years Active: 1995-2020

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10654878 - Compounds of phosphinanes and azaphosphinanes, a process for their preparation and pharmaceutical compositions containing them (2020-05-19),

2. 10138260 - Compounds of phosphinanes and azaphosphinanes, a process for their preparation and pharmaceutical compositions containing them (2018-11-27),

3. 8404742 - Diosmetin compounds, a process for their preparation and pharmaceutical compositions containing them (2013-03-26),

4. 8309341 - 2-mercaptocyclopentanecarboxylic acid compounds, a process for their preparation and pharmaceutical compositions containing them (2012-11-13),

5. 8138223 - Diosmetin compounds, a process for their preparation and pharmaceutical composition containing them (2012-03-20),

6. 7981920 - Addition salts of angiotensin-converting enzyme inhibitors with no donor acids, a process for their preparation and pharmaceutical compositions containing them (2011-07-19),

7. 7498330 - 4-oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds (2009-03-03),

8. 7265220 - Amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative (2007-09-04),

9. 6686358 - Bicyclic amino-pyrazinone compounds (2004-02-03),

10. 6302837 - Benzothiophene, benzofuran and indole compounds (2001-10-16),

11. 6288077 - 2,3-methano-amino acid compounds (2001-09-11),

12. 6277851 - Bicyclic amino-pyrazinone compounds (2001-08-21),

13. 6048875 - Benzothiophene, benzofuran and indole compounds (2000-04-11),

14. 5814622 - Compounds derived from boronic acid (1998-09-29),

15. 5786330 - Peptide compounds which are therapeutically active in the cascade of (1998-07-28),

Title: The Innovative Contributions of Alain Rupin

Introduction

Alain Rupin is a notable inventor based in Savonnieres, France, recognized for his significant contributions to the field of pharmaceuticals. With a total of 17 patents to his name, Rupin has made strides in developing compounds that have the potential to impact medical treatments.

Latest Patents

Among his latest patents are innovative compounds of phosphinanes and azaphosphinanes, along with processes for their preparation and pharmaceutical compositions containing them. These compounds are particularly noteworthy for their medicinal applications, specifically in treating conditions that require a TAFIa inhibitor. The compounds of formula (I) that he has developed include various structural configurations, showcasing his expertise in medicinal chemistry.

Career Highlights

Throughout his career, Alain Rupin has worked with prominent companies such as Adir Et Compagnie and Les Laboratoires Servier. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in the pharmaceutical industry.

Collaborations

Rupin has collaborated with esteemed colleagues, including Tony Verbeuren and Guillaume De Nanteuil, further enhancing the innovative projects he has been involved in.

Conclusion

Alain Rupin's work exemplifies the spirit of innovation in the pharmaceutical field, with his patents paving the way for new medicinal products. His contributions are invaluable, and his ongoing research continues to hold promise for future advancements in healthcare.